试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- Bayer AG
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- Male
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to compare how much of the study treatment finerenone gets into the blood when the same amount is taken in one and in two tablets in healthy male participantsCTIS2022-502385-24-00Bayer AG60
进行中（未招募）
1 期
First-in-human study of 225Ac-PSMA-Trillium (BAY 3563254) in participants with advanced metastatic castration-resistant prostate cancer (mCRPC)Advanced metastatic castration-resistant prostate cancer with prostate specific membrane antigen (PSMA) expressionMedDRA version: 21.1Level: LLTClassification code: 10076506Term: Castration-resistant prostate cancer Class: 10029104CTIS2023-507486-26-00Bayer Consumer Care AG135
招募中
1 期
A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 yearsCTIS2023-508447-52-00Bayer AG20
进行中（未招募）
1 期
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participantsCTIS2023-508905-26-00Bayer AG40
招募中
1 期
A first in human single dose escalation study to investigate the safety, tolerability, pharmacokinetics, and pharmcodynamics of BAY 3389934 compared with placebo.Sepsis associated disseminated intravascular coagulationMedDRA version: 22.0Level: PTClassification code: 10013442Term: Disseminated intravascular coagulation Class: 100000004851MedDRA version: 20.0Level: PTClassification code: 10040047Term: Sepsis Class: 100000004862CTIS2022-502866-25-00Bayer AG86